Tardive Dyskinesia Market to Witness Growth by 2032 | Companies includes Addex Therapeutics, Contera Pharma, Teva Pharmaceutical, SOM Biotech, Mitsubishi Tanabe Pharma

DelveInsight's "Tardive Dyskinesia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Tardive Dyskinesia, historical and forecasted epidemiology as well as the Tardive Dyskinesia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Tardive Dyskinesia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Tardive Dyskinesia market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Tardive Dyskinesia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Tardive Dyskinesia market.

Request for a Free Sample Report @ https://www.delveinsight.com/sample-request/tardive-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key highlights from the Tardive Dyskinesia Market Report:

The Tardive Dyskinesia Market is poised for growth, driven by increasing awareness of the disease and the development of more effective treatments.
Key players in the market include Addex Therapeutics, Contera Pharma, Teva Pharmaceutical, SOM Biotech, Mitsubishi Tanabe Pharma, and other leading companies.
In November 2023, Neurocrine Biosciences announced a study of Phase 4 clinical trials for Valbenazine. In participants with tardive dyskinesia (TD) who are receiving valbenazine for up to 24 weeks, this study will measure the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect.

Tardive Dyskinesia Overview

Tardive Dyskinesia (TD) is a movement disorder characterized by repetitive, involuntary movements, most commonly affecting the face, tongue, and limbs. It often results from long-term use of antipsychotic medications, particularly first-generation (typical) antipsychotics. TD can be distressing and impair daily functioning, leading to significant impacts on a person's quality of life.

Signs and Symptoms

- Facial Movements: Involuntary grimacing, lip smacking, or tongue protrusion.
- Limbs and Body Movements: Involuntary movements of the arms, legs, or torso, including writhing or jerky motions.
- Postural Issues: Difficulty maintaining steady posture or balance.

Causes

- Medication-Induced: Primarily caused by prolonged use of antipsychotic drugs, especially first-generation antipsychotics. Second-generation antipsychotics are less likely but can still cause TD.
- Neurobiological Factors: Imbalances in neurotransmitters, particularly dopamine, play a significant role in the development of TD.
- Genetic Predisposition: Some individuals may be genetically predisposed to developing TD when exposed to certain medications.

Diagnosis

- Clinical Evaluation: Diagnosis is primarily based on clinical observation of symptoms and a history of antipsychotic medication use.
- Exclusion of Other Conditions: It's important to differentiate TD from other movement disorders and conditions that may present with similar symptoms.
- Neurological Assessment: May involve neurological examinations to assess the extent and nature of involuntary movements.

Treatment Options

- Medication Adjustments: Switching to or adjusting the dosage of antipsychotic medications, particularly using second-generation antipsychotics, which are less likely to cause TD.
- Medications for TD: Specific treatments for TD include:
- VMAT2 Inhibitors: Such as valbenazine and deutetrabenazine, which target the vesicular monoamine transporter 2 to reduce involuntary movements.
- Anticholinergic Agents: Though less commonly used due to their limited effectiveness and potential side effects.
- Other Medications: Such as benzodiazepines and certain antidepressants, may be prescribed based on individual patient needs.
- Supportive Therapies: Including physical therapy, occupational therapy, and speech therapy, to help manage symptoms and improve quality of life.

Outlook

The Tardive Dyskinesia market is expected to expand as awareness of the condition grows and more effective treatment options become available. Advances in drug development and increased focus on managing TD are likely to enhance patient outcomes and treatment options.

Learn more about Tardive Dyskinesia, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/report-store/tardive-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Tardive Dyskinesia Market

The Tardive Dyskinesia market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Tardive Dyskinesia market trends by analyzing the impact of current Tardive Dyskinesia therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Tardive Dyskinesia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Tardive Dyskinesia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Tardive Dyskinesia market in 7MM is expected to witness a major change in the study period 2019-2032.

Request a sample and discover more about the report offerings at:
https://www.delveinsight.com/sample-request/tardive-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Tardive Dyskinesia Epidemiology

The Tardive Dyskinesia epidemiology section provides insights into the historical and current Tardive Dyskinesia patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Tardive Dyskinesia market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Tardive Dyskinesia Epidemiology at: https://www.delveinsight.com/report-store/tardive-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Tardive Dyskinesia Pipeline Development Activities

The Tardive Dyskinesia report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Tardive Dyskinesia key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Tardive Dyskinesia pipeline development activities at: https://www.delveinsight.com/sample-request/tardive-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Tardive Dyskinesia Therapeutics Assessment

Major key companies such as Addex Therapeutics, Contera Pharma, Teva Pharmaceutical, SOM Biotech, Mitsubishi Tanabe Pharma, and others are working proactively in the Tardive Dyskinesia Therapeutics market to develop novel therapies which will drive the Tardive Dyskinesia treatment markets in the upcoming years.

Learn more about the emerging therapies & key companies at: https://www.delveinsight.com/report-store/tardive-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Tardive Dyskinesia Report Key Insights

1. Tardive Dyskinesia Patient Population
2. Tardive Dyskinesia Market Size and Trends
3. Key Cross Competition in the Tardive Dyskinesia Market
4. Tardive Dyskinesia Market Dynamics (Key Drivers and Barriers)
5. Tardive Dyskinesia Market Opportunities
6. Tardive Dyskinesia Therapeutic Approaches
7. Tardive Dyskinesia Pipeline Analysis
8. Tardive Dyskinesia Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Tardive Dyskinesia Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Tardive Dyskinesia Competitive Intelligence Analysis
4. Tardive Dyskinesia Market Overview at a Glance
5. Tardive Dyskinesia Disease Background and Overview
6. Tardive Dyskinesia Patient Journey
7. Tardive Dyskinesia Epidemiology and Patient Population
8. Tardive Dyskinesia Treatment Algorithm, Current Treatment, and Medical Practices
9. Tardive Dyskinesia Unmet Needs
10. Key Endpoints of Tardive Dyskinesia Treatment
11. Tardive Dyskinesia Marketed Products
12. Tardive Dyskinesia Emerging Therapies
13. Tardive Dyskinesia Seven Major Market Analysis
14. Attribute Analysis
15. Tardive Dyskinesia Market Outlook (7 major markets)
16. Tardive Dyskinesia Access and Reimbursement Overview
17. KOL Views on the Tardive Dyskinesia Market
18. Tardive Dyskinesia Market Drivers
19. Tardive Dyskinesia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Tardive Dyskinesia Market report here: https://www.delveinsight.com/report-store/tardive-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Us:

Kritika Rehani
info@delveinsight.com
+14699457679
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.